ECSP034798A - Amidas de acido benzofuran-2-carboxílico sustituidas - Google Patents

Amidas de acido benzofuran-2-carboxílico sustituidas

Info

Publication number
ECSP034798A
ECSP034798A EC2003004798A ECSP034798A ECSP034798A EC SP034798 A ECSP034798 A EC SP034798A EC 2003004798 A EC2003004798 A EC 2003004798A EC SP034798 A ECSP034798 A EC SP034798A EC SP034798 A ECSP034798 A EC SP034798A
Authority
EC
Ecuador
Prior art keywords
diseases
treatment
cerebral
disorders
amidas
Prior art date
Application number
EC2003004798A
Other languages
English (en)
Inventor
Dieter Dorsch
Gerd Bartoszyk
Henning Boettcher
Amsterdam Christoph Van
Wilfried Rautenberg
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP034798A publication Critical patent/ECSP034798A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

donde D, R1, R2 y n tienen los significados mencionados en la reivindicación 1, son potentes agonistas de 5-HT1A e inhibidores de la reabsorción de 5-HT y son apropiados para el tratamiento de depresiones, estados de angustia, ataques de pánico, trastornos obsesivos enfermedades psiquiátricas, infartos cerebrales, isquemia cerebral, estados de ansiedad, de efectos secundarios del tratamiento de la hipertensión sanguínea, para la prevención y el tratamiento de enfermedades cerebrales, acromegalia, hipogonadismo, amenorrea secundaria, síndrome premenstrual, lactancia puerperal no deseada, dolor, trastornos del sueño, narcolepsia, enfermedades bipolares, manías, demencia, enfermedades adictivas, disfunciones sexuales, trastornos de la alimentación, obesidad o fibromialgia.
EC2003004798A 2001-03-14 2003-10-09 Amidas de acido benzofuran-2-carboxílico sustituidas ECSP034798A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10112151A DE10112151A1 (de) 2001-03-14 2001-03-14 Substituierte Benzofuran-2-carbonsäureamide

Publications (1)

Publication Number Publication Date
ECSP034798A true ECSP034798A (es) 2003-12-01

Family

ID=7677358

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004798A ECSP034798A (es) 2001-03-14 2003-10-09 Amidas de acido benzofuran-2-carboxílico sustituidas

Country Status (20)

Country Link
US (1) US7244846B2 (es)
EP (1) EP1368346A1 (es)
JP (1) JP4485743B2 (es)
KR (1) KR20030080083A (es)
CN (1) CN1244578C (es)
AR (1) AR035782A1 (es)
BR (1) BR0208040A (es)
CA (1) CA2440726C (es)
CZ (1) CZ20032712A3 (es)
DE (1) DE10112151A1 (es)
EC (1) ECSP034798A (es)
EE (1) EE200300447A (es)
HU (1) HUP0303449A3 (es)
IL (1) IL157889A0 (es)
MX (1) MXPA03008140A (es)
PL (1) PL362844A1 (es)
RU (1) RU2003129057A (es)
SK (1) SK12492003A3 (es)
WO (1) WO2002083666A1 (es)
ZA (1) ZA200307966B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
DE10306941A1 (de) * 2003-02-18 2004-08-26 Merck Patent Gmbh Benzofuranoxyethylamine
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
DE102005019670A1 (de) * 2005-04-26 2006-11-02 Merck Patent Gmbh Verfahren zur Herstellung von (5-(4-[4-(5-Cyano-3-indolyl)-butyl)-1-piperazinyl)-benzofuran-2-carboxamid
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
DE102006060597A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Verfahren zur Herstellung von Benzofuran-2-carboxamiden
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
KR20100134664A (ko) * 2008-03-14 2010-12-23 메르크 파텐트 게엠베하 중추신경계 장애들의 치료를 위한 아자인돌 화합물들
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
KR101361145B1 (ko) * 2011-03-10 2014-02-12 한국화학연구원 신규한 벤조퓨란-2-카르복사미드 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
WO2016192657A1 (en) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders

Also Published As

Publication number Publication date
PL362844A1 (en) 2004-11-02
IL157889A0 (en) 2004-03-28
HUP0303449A2 (hu) 2004-01-28
CA2440726A1 (en) 2002-10-24
US7244846B2 (en) 2007-07-17
ZA200307966B (en) 2005-01-13
DE10112151A1 (de) 2002-09-19
MXPA03008140A (es) 2003-12-12
JP4485743B2 (ja) 2010-06-23
KR20030080083A (ko) 2003-10-10
RU2003129057A (ru) 2005-04-10
CA2440726C (en) 2011-05-17
CN1494543A (zh) 2004-05-05
EE200300447A (et) 2003-12-15
JP2004527536A (ja) 2004-09-09
SK12492003A3 (sk) 2004-03-02
WO2002083666A1 (en) 2002-10-24
CN1244578C (zh) 2006-03-08
EP1368346A1 (en) 2003-12-10
AR035782A1 (es) 2004-07-14
HUP0303449A3 (en) 2005-02-28
CZ20032712A3 (cs) 2004-01-14
BR0208040A (pt) 2004-02-25
US20050075269A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
ECSP034798A (es) Amidas de acido benzofuran-2-carboxílico sustituidas
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
ATE479686T1 (de) Pyridopyrrolizin- und pyridoindolizinderivate
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
NO20054200L (no) Pyrazoler samt fremgangsmate for fremstilling derav
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
CY1106011T1 (el) Χρηση αναστολεων κινασης τυροσινης για την αγωγη αλλepγικων παθησεων
WO2001079169A3 (en) Prostaglandin d2 receptor antagonists
WO2003045918A8 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO2013008I2 (no) Krizotinib eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav
WO2001045730A3 (en) Tweak receptor
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
DK1140945T3 (da) Kondenserede 1,2,4-thiadiazinderivater, deres fremstilling og anvendelse
IL162203A0 (en) Indolinone derivatives useful as protein inase inhibitors
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
CY1105930T1 (el) Χρηση αναστολεων c-kit για θepαπεια ασθενειων φλεγμονωδους εντερου (ibd)
EP1254662A3 (en) Methods and kits for treating depression or preventing deterioration of cognitive function
NO20055741D0 (no) Nye kjemiske forbindelser